CASI Pharmaceuticals
CASI
CASI was delisted on the 25th of February, 2026.
58 hedge funds and large institutions have $44.4M invested in CASI Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 21 increasing their positions, 15 reducing their positions, and 4 closing their positions.
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
40% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 15
9% more funds holding
Funds holding: 53 → 58 (+5)
0.07% more ownership
Funds ownership: 2.12% → 2.2% (+0.07%)
30% less capital invested
Capital invested by funds: $63.2M → $44.4M (-$18.8M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$2.48M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$344K |
| 3 |
BFM
Boothbay Fund Management
New York
|
+$332K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$120K |
| 5 |
WSC
Wellington Shields & Co
New York
|
+$91.3K |
Top Sellers
| 1 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$213K |
| 2 |
Morgan Stanley
New York
|
-$153K |
| 3 |
State Street
Boston,
Massachusetts
|
-$103K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$89.3K |
| 5 |
Barclays
London,
United Kingdom
|
-$80.6K |
CASI Hedge Fund Activity: Q1 2020 in Review
58 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q1 2020, worth a combined $44.4M — down 30% from $63.2M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new CASI positions and 4 closed out — a net gain of 7 holders — while 21 added to existing stakes and 15 trimmed.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $2.48M. The largest seller was State of Wisconsin Investment Board, exiting entirely with an estimated $213K sold.
- 58 institutional investors held CASI Pharmaceuticals (CASI) as of Q1 2020, up from 53 in Q4 2019.
- Funds reported $44.4M of CASI Pharmaceuticals stock for Q1 2020, down 30% quarter-over-quarter.
- 11 funds opened new CASI Pharmaceuticals positions in Q1 2020 and 4 closed out, a net change of +7 holders.
- The largest CASI Pharmaceuticals buyer in Q1 2020 was Ikarian Capital, an estimated $2.48M added.
- The largest CASI Pharmaceuticals seller in Q1 2020 was State of Wisconsin Investment Board, an estimated $213K sold.
Based on aggregated 13F filings for Q1 2020.